Abstract:Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. It is estimated that 13,410 cases will be diagnosed and 8,990 will die of AML in the United States in 2007 (http://seer.cancer.gov). AML is a genetically diverse hematopoietic malignancy with variable response to treatment. Expression profiling of protein-coding genes using DNA microarray in AML has resulted in inconsistent data from different laboratories. Therefore, further validation of these observations in large cohorts and in independent studies is definitely required before clinical application becomes feasible. Recently, Golub and colleagues described a new, bead-based flow cytometric microRNA (miRNAs, miRs) expression profiling method that could successfully classify tumors. MiRNAs are endogenous ∼22 nucleotide non-coding RNAs, which can function as oncogenes and tumor suppressors. To provide new insights into the complex genetic alterations in leukemogenesis and to identify novel markers for diagnosis and treatment of AML, we performed a genome-wide analysis of miRNA expression profiles using the bead-based method on 54 AML samples with common translocations including t(15;17), t(8;21), inv(16), and 11q23 rearrangement, along with normal controls. In both unsupervised and supervised hierarchical cluster analyses, we observed that t(15;17) samples grouped together as one cluster, as do the 11q23 rearrangement samples. Interestingly, t(8;21) and inv(16), both CBF (core-binding factor) AMLs, grouped together as a unique cluster. Forty-one miRNAs exhibited significantly differential expression between different subtypes of AMLs, and/or between AMLs and normal controls. Notably, expression signature of a minimal number of two, three, and seven miRNAs could be used for class prediction of CBF, t(15;17), and 11q23 rearrangement AMLs, respectively, with an overall diagnostic accuracy of 94–96%. We further showed that overexpression of the two discriminatory miRNAs in CBF AML is associated with epigenetic regulation, rather than DNA copy number amplification. Moreover, several important target genes of these discriminatory miRNAs have also been validated. We are currently exploring the role of these discriminatory miRNAs and their critical target genes in the development of AML using in vitro and in vivo models. This work will enhance our understanding of the biological role of these miRNAs and their targets in leukemogenesis.

3′CBFB deletion in CBFB-rearranged acute myeloid leukemia retains morphological features associated with inv(16), but patients have higher risk of relapse and may require stem cell transplant

Unusual Findings Of Acute Myeloid Leukemia With Inv(3)(Q21q26.2) Or T(3;3)(Q21;Q26.2): A Multicenter Study

Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia

Cytogenetic Analysis of 1863 Chineses Patients with Chronic Myeloid Leukemia

FLT3-ITD As a Prognostic Factor for Chinese Patients with Acute Myeloid Leukemia

CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease

MicroRNA Expression Profiles in Acute Myeloid Leukemia with Common Translocations.

Clinical Analysis of 24 Cases of Acute Myeloid Leukemia with 3q Abnormalities

Integrative immunophenotypic and genetic characterization of acute myeloid leukemia with CBFB rearrangement

Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11

Clinical Characteristics and Prognostic Factors Analysis of Core Binding Factor Acute Myeloid Leukemia in Real World.

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

Classifying AML Patients with Inv(16) into High-Risk and Low-Risk Relapsed Patients Based on Peritransplantation Minimal Residual Disease Determined by CBFÎ²/MYH11 Gene Expression

An Acute Myeloid Leukemia Case with Concurrent 11q23 Anomaly and D13S319 Deficiency Diagnosed by Combined Inter- and Metaphase Fluorescence in Situ Hybridization

Loss of the Inv(16) Oncogene CBFB::MYH11 Eliminates Leukemia from the Blood and Spleen, but not the Bone Marrow

The Lost or Absence of MRD < 0.1% at Any Time after 2 Cycles of Consolidation Chemotherapy in CBFB-MYH11-Positive Acute Myeloid Leukemia Indicates Poor Prognosis

Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations

The Loss or Absence of Minimal Residual Disease of <0·1% at Any Time after Two Cycles of Consolidation Chemotherapy in CBFB–MYH11‐positive Acute Myeloid Leukaemia Indicates Poor Prognosis

Favorable Outcome Of Allogenic Stem Cell Transplant In Patients With Acute Myeloid Leukemia Carrying T(6;9)(P22;Q34) / Dek-Nup214 Rearrangement

How to Improve Prognostication in Acute Myeloid Leukemia with CBFB-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring

Clinical Analysis of Pediatric Acute Megakaryocytic Leukemia With CBFA2T3-GLIS2 Fusion Gene